Ernexa Therapeutics Inc. (ERNA)
ERNA moved a median of -0.59% 30 minutes after news, and -1.32% by the close. How ERNA actually reacts to news — the realized, point-in-time move the market made, measured across 207 labeled events over the last three years with zero look-ahead.
ERNA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 36% | 180 |
| 30-min | -0.59% | 40% | 198 |
| 60-min | -0.19% | 43% | 201 |
| to close | -1.32% | 40% | 205 |
| Middle 50% of ERNA reactions | -3.71% to +1.91% |
|---|---|
| Median reaction (30-min) | -0.59% |
| Measured reactions | 207 |
Half of all Ernexa Therapeutics Inc. news events land between -3.71% and +1.91% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when ERNA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ERNA's baseline. Nothing else.
Recent ERNA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Ernexa Therapeutics Inc. For: Oct 15 | SEC filing · Form 8-K | SEC EDGAR | — | -4.57% | |
| Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series | Press release | GlobeNewswire | +0.00% | +0.91% | |
| Ernexa Therapeutics’ ERNA-101 Selected for Flash Talk Presentation at Nature Conferences’ Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer Center | Press release | GlobeNewswire | -0.36% | -18.73% | |
| Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic | Press release | GlobeNewswire | +0.00% | -5.43% | |
| Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND | Press release | GlobeNewswire | +2.93% | -1.24% | |
| Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy | Press release | GlobeNewswire | — | -7.87% | |
| Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D., FACP, to Board of Directors | Press release | GlobeNewswire | +0.99% | -6.93% | |
| Form 8-K Ernexa Therapeutics Inc. For: Sep 14 | SEC filing · Form 8-K | SEC EDGAR | +0.99% | -6.93% | |
| Form 8-K Ernexa Therapeutics Inc. For: Sep 16 | SEC filing · Form 8-K | SEC EDGAR | +0.99% | -6.93% | |
| Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First-in-Human Dosing | Press release | GlobeNewswire | -1.06% | +7.94% | |
| Ernexa Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference | Press release | GlobeNewswire | +0.00% | +3.39% | |
| Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference | Press release | GlobeNewswire | — | -4.54% | |
| Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage | Press release | GlobeNewswire | +3.77% | — | |
| Form 10-Q Ernexa Therapeutics Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | — | -3.88% | |
| Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies | Press release | GlobeNewswire | +0.00% | -3.68% | |
| Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry | Press release | GlobeNewswire | +14.69% | -21.56% | |
| Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026 | Press release | GlobeNewswire | +0.00% | +2.89% | |
| Form 8-K Ernexa Therapeutics Inc. For: Jul 01 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +2.06% | |
| Form 8-K Ernexa Therapeutics Inc. For: Jul 02 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +2.06% | |
| Form 8-K Ernexa Therapeutics Inc. For: Jun 22 | SEC filing · Form 8-K | SEC EDGAR | — | +1.74% | |
| Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients | Press release | GlobeNewswire | +0.31% | +14.20% | |
| Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study | Press release | GlobeNewswire | +1.88% | -7.83% | |
| Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer | Press release | GlobeNewswire | +1.75% | -8.36% | |
| Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development | Press release | GlobeNewswire | +0.00% | -2.88% | |
| Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity | Press release | GlobeNewswire | +2.23% | +5.95% | |
| Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101 | Press release | GlobeNewswire | -1.76% | -2.57% | |
| Form 10-Q Ernexa Therapeutics Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.54% | +60.99% | |
| Form ARS Ernexa Therapeutics Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -1.54% | +60.99% | |
| Form DEF 14A Ernexa Therapeutics Inc. For: May 11 | SEC filing · Form DEF | SEC EDGAR | -1.54% | +60.99% | |
| Form DEFA14A Ernexa Therapeutics Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -1.54% | +60.99% | |
| Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models | Press release | GlobeNewswire | -12.46% | +3.07% | |
| Form 8-K Ernexa Therapeutics Inc. For: May 01 | SEC filing · Form 8-K | SEC EDGAR | -1.52% | +1.27% | |
| Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split | Press release | GlobeNewswire | -3.83% | -4.16% | |
| Form DEF 14C Ernexa Therapeutics Inc. For: Apr 13 | SEC filing · Form DEF | SEC EDGAR | -5.62% | -3.00% | |
| Form PRE 14C Ernexa Therapeutics Inc. For: Apr 01 | SEC filing · Form PRE | SEC EDGAR | +2.48% | -0.74% | |
| Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026 | Press release | GlobeNewswire | -2.44% | +2.31% | |
| Form EFFECT Ernexa Therapeutics Inc. | SEC filing · Form EFFECT | SEC EDGAR | -2.44% | +2.31% | |
| Form S-3/A Ernexa Therapeutics Inc. | SEC filing · Form S-3 | SEC EDGAR | -3.12% | -0.57% | |
| Form 8-K Ernexa Therapeutics Inc. For: Mar 18 | SEC filing · Form 8-K | SEC EDGAR | -1.84% | -7.84% | |
| Form S-3 Ernexa Therapeutics Inc. | SEC filing · Form S-3 | SEC EDGAR | +0.00% | +0.67% | |
| Form 10-K Ernexa Therapeutics Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | +0.67% | |
| Form 8-K Ernexa Therapeutics Inc. For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | +2.21% | -1.69% | |
| Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series | Press release | GlobeNewswire | -1.85% | -11.56% | |
| Form 8-K Ernexa Therapeutics Inc. For: Feb 06 | SEC filing · Form 8-K | SEC EDGAR | -2.44% | +18.34% | |
| Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering | Press release | GlobeNewswire | -4.45% | -5.92% | |
| Form EFFECT Ernexa Therapeutics Inc. | SEC filing · Form EFFECT | SEC EDGAR | -4.45% | -5.92% | |
| Form 8-A12B Ernexa Therapeutics Inc. | SEC filing · Form 8-A12B | SEC EDGAR | +2.33% | -7.14% | |
| Form CERT Ernexa Therapeutics Inc. | SEC filing · Form CERT | SEC EDGAR | -0.13% | -0.19% | |
| Form S-1/A Ernexa Therapeutics Inc. | SEC filing · Form S-1 | SEC EDGAR | — | -13.94% | |
| Form S-1/A Ernexa Therapeutics Inc. | SEC filing · Form S-1 | SEC EDGAR | -7.95% | -7.88% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ERNA section they belong to.
Where else ERNA is measured.
ERNA earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Ernexa Therapeutics Inc.'s median reaction calculated?
Every labeled ERNA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 207 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 40% of ERNA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ERNA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.